Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 6/20 | 0.40 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17794961 | 0.83 | CHRM1 (0.44) | CHRM1CHRM5ERN1 | |
| SCHEMBL17809692 | 0.82 | USP30 (0.42) | USP30BRD4CREBBPRETGRM4 | |
| SCHEMBL19538863 | 0.79 | BRD4 (0.47) | USP30BRD4CREBBPGRM4BAZ2B | |
| SCHEMBL17806584 | 0.79 | LRRK2 (0.41) | USP30BRD4CREBBPRETGRM4 | |
| SCHEMBL19531703 | 0.76 | LRRK2 (0.48) | USP30BRD4CREBBPCNR1CNR2 | |
| SCHEMBL17795290 | 0.75 | USP30 (0.39) | USP30RETSRPK2SRPK1EML4 | |
| SCHEMBL23761239 | 0.75 | PIK3CD (0.47) | USP30RETRIPK3CNR1CNR2 | |
| SCHEMBL17809747 | 0.72 | USP30 (0.50) | USP30CREBBPRETCNR1CNR2 | |
| SCHEMBL25378962 | 0.72 | CYP11B1 (0.48) | RETRIPK3CNR1CNR2 | |
| SCHEMBL17795599 | 0.72 | USP30 (0.39) | USP30CREBBPRETSRPK2SRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | USP30 2156/4885BRD4 11/4885CREBBP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.